{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T04:59:58Z","timestamp":1787979598311,"version":"build-2784847793"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T00:00:00Z","timestamp":1750896000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020581","name":"Fondazione AIRC per la ricerca sul cancro ETS","doi-asserted-by":"publisher","award":["21267"],"award-info":[{"award-number":["21267"]}],"id":[{"id":"10.13039\/100020581","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.eclinm.2025.103354","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T21:59:07Z","timestamp":1752616747000},"page":"103354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Exploring patient-reported outcomes and morbidity burden of patients with VEXAS syndrome: a scoping review"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5065-5166","authenticated-orcid":false,"given":"Fabio","family":"Efficace","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-0026-9548","authenticated-orcid":false,"given":"Daniela","family":"Krepper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Sparano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Fazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Voso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6829-5544","authenticated-orcid":false,"given":"Carmelo","family":"Gurnari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"27","key":"10.1016\/j.eclinm.2025.103354_bib1","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1056\/NEJMoa2026834","article-title":"Somatic mutations in UBA1 and severe adult-onset autoinflammatory disease","volume":"383","author":"Beck","year":"2020","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103354_bib2","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1182\/blood.2023023723","article-title":"Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes","volume":"144","author":"Sirenko","year":"2024","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.eclinm.2025.103354_bib3","first-page":"3591","article-title":"VEXAS syndrome","volume":"137","author":"Grayson","year":"2021","journal-title":"Blood"},{"issue":"13","key":"10.1016\/j.eclinm.2025.103354_bib4","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1182\/blood.2022016985","article-title":"Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis","volume":"140","author":"Ferrada","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103354_bib5","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jaci.2023.02.017","article-title":"Autoimmune manifestations in VEXAS: opportunities for integration and pitfalls to interpretation","volume":"151","author":"Bruno","year":"2023","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103354_bib6","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/ajh.27169","article-title":"Diagnostic capabilities, clinical features, and longitudinal UBA1 clonal dynamics of a nationwide VEXAS cohort","volume":"99","author":"Gurnari","year":"2024","journal-title":"Am J Hematol"},{"issue":"26","key":"10.1016\/j.eclinm.2025.103354_bib7","doi-asserted-by":"crossref","first-page":"3685","DOI":"10.1182\/blood.2021010811","article-title":"Vacuolization of hematopoietic precursors: an enigma with multiple etiologies","volume":"137","author":"Gurnari","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103354_bib8","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000775","article-title":"UBA1 screening in sweet syndrome with hematological neoplasms reveals a novel association between VEXAS and chronic myelomonocytic leukemia","volume":"6","author":"Gurnari","year":"2022","journal-title":"Hemasphere"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103354_bib9","article-title":"New scenarios in Vacuoles, E1 enzyme, X linked, Autoinflammatory, Somatic (VEXAS) syndrome: evolution from myelodysplastic syndrome to acute myeloid leukemia","volume":"71","author":"Battipaglia","year":"2023","journal-title":"Curr Res Transl Med"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103354_bib10","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/bjd.20805","article-title":"Further characterization of clinical and laboratory features in VEXAS syndrome: large-scale analysis of a multicentre case series of 116 French patients","volume":"186","author":"Georgin-Lavialle","year":"2022","journal-title":"Br J Dermatol"},{"issue":"21","key":"10.1016\/j.eclinm.2025.103354_bib11","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1182\/blood.2023022329","article-title":"Venous and arterial thrombosis in patients with VEXAS syndrome","volume":"143","author":"Kusne","year":"2024","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103354_bib12","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1182\/bloodadvances.2023012478","article-title":"Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT","volume":"8","author":"Gurnari","year":"2024","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103354_bib13","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1038\/s41409-022-01774-8","article-title":"Update on VEXAS and role of allogeneic bone marrow transplant: Considerations on behalf of the Chronic Malignancies Working Party of the EBMT","volume":"57","author":"Gurnari","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103354_bib14","doi-asserted-by":"crossref","first-page":"3565","DOI":"10.1007\/s10067-024-07160-7","article-title":"Allogenic haematopoietic stem cell transplantation in VEXAS: a review of 33 patients","volume":"43","author":"Ali","year":"2024","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103354_bib15","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/ajh.27156","article-title":"VEXAS syndrome: clinical, hematologic features and a practical approach to diagnosis and management","volume":"99","author":"Koster","year":"2024","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103354_bib16","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/bjh.19897","article-title":"Methodology and clinical utility of longitudinal UBA1 tracking in VEXAS syndrome","volume":"206","author":"Gurnari","year":"2025","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103354_bib17","first-page":"253","article-title":"VEXAS syndrome: is it more a matter of inflammation or hematopoietic clonality? A case series approach to diagnosis, therapeutic strategies and transplant management","volume":"104","author":"Costa","year":"2025","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103354_bib18","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s41687-021-00336-8","article-title":"Measuring health-related quality of life in patients with rare disease","volume":"5","author":"Lenderking","year":"2021","journal-title":"J Patient Rep Outcomes"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103354_bib19","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1007\/s11764-022-01324-7","article-title":"Quality of life of patients with rare cancer: a comparison with patients with colorectal cancer and the association with disease trajectory-related factors","volume":"17","author":"Driehuis","year":"2023","journal-title":"J Cancer Surviv"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103354_bib20","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1182\/blood-2017-03-737403","article-title":"Patient-reported outcomes in hematology: is it time to focus more on them in clinical trials and hematology practice?","volume":"130","author":"Efficace","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103354_bib21","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s12874-018-0611-x","article-title":"Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach","volume":"18","author":"Munn","year":"2018","journal-title":"BMC Med Res Methodol"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103354_bib22","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103354_bib23","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103354_bib24","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"issue":"26","key":"10.1016\/j.eclinm.2025.103354_bib25","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1182\/blood.2020010177","article-title":"Therapeutic options in VEXAS syndrome: insights from a retrospective series","volume":"137","author":"Bourbon","year":"2021","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103354_bib26","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1002\/art.41743","article-title":"Somatic mutations in UBA1 define a distinct subset of relapsing polychondritis patients with VEXAS","volume":"73","author":"Ferrada","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"16","key":"10.1016\/j.eclinm.2025.103354_bib27","doi-asserted-by":"crossref","first-page":"3203","DOI":"10.1182\/bloodadvances.2021004976","article-title":"Benign and malignant hematologic manifestations in patients with VEXAS syndrome due to somatic mutations in UBA1","volume":"5","author":"Obiorah","year":"2021","journal-title":"Blood Adv"},{"issue":"26","key":"10.1016\/j.eclinm.2025.103354_bib28","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood.2020010286","article-title":"Novel somatic mutations in UBA1 as a cause of VEXAS syndrome","volume":"137","author":"Poulter","year":"2021","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103354_bib29","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1111\/bjh.17893","article-title":"Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry","volume":"196","author":"Comont","year":"2022","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103354_bib30","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/blood.2022016642","article-title":"Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study","volume":"140","author":"Heiblig","year":"2022","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103354_bib31","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1038\/s41375-022-01698-8","article-title":"A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune\/inflammatory disorders and VEXAS syndrome associated with MDS and CMML","volume":"36","author":"Mekinian","year":"2022","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103354_bib32","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.jaci.2021.05.014","article-title":"Adult-onset autoinflammation caused by somatic mutations in UBA1: a Dutch case series of patients with VEXAS","volume":"149","author":"van der Made","year":"2022","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103354_bib33","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2022-002255","article-title":"Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patients","volume":"8","author":"Khitri","year":"2022","journal-title":"RMD Open"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103354_bib34","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1001\/jama.2022.24836","article-title":"Estimated prevalence and clinical manifestations of UBA1 variants associated with VEXAS syndrome in a clinical population","volume":"329","author":"Beck","year":"2023","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103354_bib35","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.chest.2022.10.011","article-title":"Pleuropulmonary manifestations of vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic (VEXAS) syndrome","volume":"163","author":"Borie","year":"2023","journal-title":"Chest"},{"key":"10.1016\/j.eclinm.2025.103354_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2023.107245","article-title":"Pulmonary manifestations in VEXAS syndrome","volume":"213","author":"Casal Moura","year":"2023","journal-title":"Respir Med"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103354_bib37","first-page":"244","article-title":"Spectrum of clonal hematopoiesis in VEXAS syndrome","volume":"142","author":"Gutierrez-Rodrigues","year":"2023","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.eclinm.2025.103354_bib38","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/ijd.16635","article-title":"Cutaneous involvement in VEXAS syndrome: clinical and histopathologic findings","volume":"62","author":"Hines","year":"2023","journal-title":"Int J Dermatol"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103354_bib39","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1136\/ard-2023-224460","article-title":"Spanish cohort of VEXAS syndrome: clinical manifestations, outcome of treatments and novel evidences about UBA1 mosaicism","volume":"82","author":"Mascaro","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.eclinm.2025.103354_bib40","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.jaad.2022.10.052","article-title":"Clinical and pathological features of cutaneous manifestations in VEXAS syndrome: a multicenter retrospective study of 59 cases","volume":"88","author":"Zakine","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103354_bib41","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000828","article-title":"Quantitative assessment of vacuolization of myeloid precursors in VEXAS syndrome","volume":"7","author":"Rabut","year":"2023","journal-title":"Hemasphere"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103354_bib42","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1136\/ard-2023-224819","article-title":"Serious infections in patients with VEXAS syndrome: data from the French VEXAS registry","volume":"83","author":"de Valence","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103354_bib43","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1136\/ard-2024-225640","article-title":"Efficacy and safety of targeted therapies in VEXAS syndrome: retrospective study from the FRENVEX","volume":"83","author":"Hadjadj","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103354_bib44","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/s41467-024-44811-4","article-title":"VEXAS syndrome is characterized by inflammasome activation and monocyte dysregulation","volume":"15","author":"Kosmider","year":"2024","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103354_bib45","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1093\/rheumatology\/kead425","article-title":"Efficient detection of somatic UBA1 variants and clinical scoring system predicting patients with variants in VEXAS syndrome","volume":"63","author":"Maeda","year":"2024","journal-title":"Rheumatology"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103354_bib46","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1001\/jamadermatol.2024.1657","article-title":"Skin manifestations of VEXAS syndrome and associated genotypes","volume":"160","author":"Tan","year":"2024","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.eclinm.2025.103354_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2024.152430","article-title":"Orbital\/ocular inflammatory involvement in VEXAS syndrome: data from the international AIDA network VEXAS registry","volume":"66","author":"Vitale","year":"2024","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103354_bib48","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1093\/rheumatology\/kead697","article-title":"Treatment experiences with focus on IL-6R inhibition in patients with VEXAS syndrome and a case of remission with azacytidine treatment","volume":"64","author":"Johansen","year":"2025","journal-title":"Rheumatology"},{"issue":"9","key":"10.1016\/j.eclinm.2025.103354_bib53","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000944","article-title":"Health-related quality of life profile of newly diagnosed patients with myelodysplastic syndromes by age, sex, and risk group: a real-world study by the GIMEMA","volume":"7","author":"Efficace","year":"2023","journal-title":"Hemasphere"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103354_bib54","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1111\/bjh.13138","article-title":"Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes","volume":"168","author":"Efficace","year":"2015","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103354_bib55","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1038\/s41375-018-0089-x","article-title":"Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study","volume":"32","author":"Stauder","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.eclinm.2025.103354_bib56","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.20157","article-title":"Erythroid-stimulating agents in VEXAS syndrome: a retrospective study from an Italian multicentre cohort","author":"Diral","year":"2025","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.eclinm.2025.103354_bib57","doi-asserted-by":"crossref","first-page":"3711","DOI":"10.1182\/blood-2024-205755","article-title":"Patient reported outcomes in Vexas syndrome","volume":"144","author":"Patel","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103354_bib58","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jval.2020.10.017","article-title":"Patient-reported outcomes as independent prognostic factors for survival in oncology: systematic review and meta-analysis","volume":"24","author":"Efficace","year":"2021","journal-title":"Value Health"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103354_bib59","doi-asserted-by":"crossref","first-page":"e685","DOI":"10.1016\/S1470-2045(19)30656-4","article-title":"Prognostic value of patient-reported outcomes from international randomised clinical trials on cancer: a systematic review","volume":"20","author":"Mierzynska","year":"2019","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103354_bib60","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/S0959-8049(99)00193-8","article-title":"Quality of life instruments in oncology","volume":"35","author":"Velikova","year":"1999","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.eclinm.2025.103354_bib61","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13023-018-0810-x","article-title":"Patient reported outcome measures in rare diseases: a narrative review","volume":"13","author":"Slade","year":"2018","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.eclinm.2025.103354_bib62","series-title":"Rare diseases: Considerations for the development of drugs and biological Products","year":"2023"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258953702500286X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S258953702500286X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T20:08:34Z","timestamp":1762632514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S258953702500286X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":58,"alternative-id":["S258953702500286X"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103354","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring patient-reported outcomes and morbidity burden of patients with VEXAS syndrome: a scoping review","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103354","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103354"}}